{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:31:57Z","timestamp":1768570317234,"version":"3.49.0"},"posted":{"date-parts":[[2025,4,28]]},"group-title":"Neurology","reference-count":71,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>INTRODUCTION<\/jats:title>\n                  <jats:p>Using the ATN framework, we evaluated the potential of plasma biomarkers to identify abnormal brain amyloid-beta (A\u03b2) positron emission tomography (PET), tau-PET and neurodegeneration in a socioeconomically disadvantaged population-based cohort.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Community-dwelling dementia-free (n=113, including 102 (91%) cognitively normal) participants underwent ATN neuroimaging and plasma biomarker assessments.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>\n                    Plasma A\u03b242\/A\u03b240, p-tau181, and p-tau217 showed significant associations with A\u03b2-PET status (adjusted odds ratio [AOR] of 1.74*10\n                    <jats:sup>-24<\/jats:sup>\n                    , 1.47, and 3.43*10\n                    <jats:sup>3<\/jats:sup>\n                    respectively [p- values&lt;0.05]), with p-tau217 demonstrating the highest classification accuracy for A\u03b2-PET status (AUC=0.94). Plasma p-tau181 and p-tau217 showed significant associations with tau- PET status (AOR: 1.50 and 22.24, respectively, p-values&lt;0.05), with comparable classification accuracies for tau-PET status (AUC=0.74 and 0.70, respectively). Only plasma NfL showed significant association with neurodegeneration based on cortical thickness (AOR=1.09, p- value&lt;0.05).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>CONCLUSION<\/jats:title>\n                  <jats:p>Our findings highlight potential of plasma p-tau217 as a biomarker for brain A\u03b2 and tau pathophysiology, p-tau181 for tau abnormalities, and NfL for neurodegeneration in the community.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.04.27.25326360","type":"posted-content","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T19:10:19Z","timestamp":1745867419000},"source":"Crossref","is-referenced-by-count":1,"title":["Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort"],"prefix":"10.64898","author":[{"given":"Menayit Tamrat","family":"Dresse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela C. L.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay","family":"Prasadan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihui L.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna","family":"Bellaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme","family":"Povala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Ilyas","family":"Kamboh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Ganguli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth E.","family":"Snitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Elizabeth","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025043020264460000_2025.04.27.25326360v1.1","first-page":"1823","article-title":"Treatment of Alzheimer Disease","volume":"30","year":"2024","journal-title":"CONTINUUM: Lifelong Learning in Neurology"},{"key":"2025043020264460000_2025.04.27.25326360v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708"},{"key":"2025043020264460000_2025.04.27.25326360v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2025043020264460000_2025.04.27.25326360v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00064-X"},{"key":"2025043020264460000_2025.04.27.25326360v1.5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007583"},{"key":"2025043020264460000_2025.04.27.25326360v1.6","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008081"},{"key":"2025043020264460000_2025.04.27.25326360v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature25456"},{"key":"2025043020264460000_2025.04.27.25326360v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2014.01.014"},{"key":"2025043020264460000_2025.04.27.25326360v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab223"},{"key":"2025043020264460000_2025.04.27.25326360v1.12","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12447"},{"key":"2025043020264460000_2025.04.27.25326360v1.13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","year":"2020","journal-title":"The Lancet Neurology"},{"key":"2025043020264460000_2025.04.27.25326360v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01925-w"},{"key":"2025043020264460000_2025.04.27.25326360v1.15","doi-asserted-by":"crossref","unstructured":"Jonaitis EM , Janelidze S , Cody KA , Langhough R , Du L , Chin NA , et al. Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease. Brain Communications. 2023;5:fcad057.","DOI":"10.1093\/braincomms\/fcad057"},{"key":"2025043020264460000_2025.04.27.25326360v1.16","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1002\/alz.12986","article-title":"Plasma biomarkers identify older adults at risk of Alzheimer\u2019s disease and related dementias in a real- world population-based cohort","volume":"19","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.17","doi-asserted-by":"crossref","first-page":"e14022","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE,","year":"2021","journal-title":"EMBO Molecular Medicine"},{"key":"2025043020264460000_2025.04.27.25326360v1.18","first-page":"e12514","article-title":"Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study","volume":"15","year":"2023","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"key":"2025043020264460000_2025.04.27.25326360v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00923-z"},{"key":"2025043020264460000_2025.04.27.25326360v1.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01306-w"},{"key":"2025043020264460000_2025.04.27.25326360v1.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02275-6"},{"key":"2025043020264460000_2025.04.27.25326360v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00665-2"},{"key":"2025043020264460000_2025.04.27.25326360v1.23","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1002\/alz.13393","article-title":"Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals","volume":"19","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease","volume":"78","year":"2021","journal-title":"JAMA Neurology"},{"key":"2025043020264460000_2025.04.27.25326360v1.25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid- positron emission tomography","volume":"14","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.26","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology","volume":"20","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.27","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","article-title":"Plasma Phosphorylated Tau 217 and A\u03b242\/40 to Predict Early Brain A\u03b2 Accumulation in People Without Cognitive Impairment","volume":"81","year":"2024","journal-title":"JAMA Neurology"},{"key":"2025043020264460000_2025.04.27.25326360v1.28","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Blennow K, for the Alzheimer\u2019s Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease","volume":"74","year":"2017","journal-title":"JAMA Neurology"},{"key":"2025043020264460000_2025.04.27.25326360v1.29","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320106"},{"key":"2025043020264460000_2025.04.27.25326360v1.30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-215730","article-title":"Blood Tests for Alzheimer\u2019s Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance","volume":"90","year":"2022","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"2025043020264460000_2025.04.27.25326360v1.31","doi-asserted-by":"crossref","unstructured":"Livingston G , Huntley J , Liu KY , Costafreda SG , Selb\u00e6k G , Alladi S , et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404:572\u2013628.","DOI":"10.1016\/S0140-6736(24)01296-0"},{"key":"2025043020264460000_2025.04.27.25326360v1.32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jrh.12155","article-title":"Rural-Urban differences in Alzheimer\u2019s disease and related disorders diagnostic prevalence in Kentucky and West Virginia","volume":"32","year":"2016","journal-title":"J Rural Health"},{"key":"2025043020264460000_2025.04.27.25326360v1.33","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1002\/alz.13104","article-title":"Global rural health disparities in Alzheimer\u2019s disease and related dementias: State of the science","volume":"19","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.34","doi-asserted-by":"crossref","unstructured":"Ganguli M , Albanese E , Seshadri S , Bennett DA , Lyketsos C , Kukull WA , et al. Population Neuroscience: Dementia Epidemiology Serving Precision Medicine and Population Health. Alzheimer Disease & Associated Disorders. 2018;32:1.","DOI":"10.1097\/WAD.0000000000000237"},{"key":"2025043020264460000_2025.04.27.25326360v1.35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s11682-020-00334-2","article-title":"Alzheimer\u2019s Disease Pathology in a Community-Based Sample of Older Adults Without Dementia: The MYHAT Neuroimaging Study","volume":"15","year":"2021","journal-title":"Brain Imaging Behav"},{"key":"2025043020264460000_2025.04.27.25326360v1.36","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2257"},{"key":"2025043020264460000_2025.04.27.25326360v1.37","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"2025043020264460000_2025.04.27.25326360v1.38","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"2025043020264460000_2025.04.27.25326360v1.39","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265941"},{"key":"2025043020264460000_2025.04.27.25326360v1.40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease","volume":"13","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.41","first-page":"e12018","article-title":"Associations between NIH Toolbox Cognition Battery and in vivo brain amyloid and tau pathology in non- demented older adults. Alzheimer\u2019s & Dementia: Diagnosis","volume":"12","year":"2020","journal-title":"Assessment & Disease Monitoring"},{"key":"2025043020264460000_2025.04.27.25326360v1.42","first-page":"e1920","article-title":"Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality","volume":"90","year":"2018","journal-title":"Neurology"},{"key":"2025043020264460000_2025.04.27.25326360v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2013.01.015"},{"key":"2025043020264460000_2025.04.27.25326360v1.44","doi-asserted-by":"crossref","unstructured":"Zeng X , Lafferty TK , Sehrawat A , Chen Y , Ferreira PCL , Bellaver B , et al. Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease. Molecular Neurodegeneration. 2024;19:68.","DOI":"10.1186\/s13024-024-00753-5"},{"key":"2025043020264460000_2025.04.27.25326360v1.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2022.11.007"},{"key":"2025043020264460000_2025.04.27.25326360v1.46","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa403"},{"key":"2025043020264460000_2025.04.27.25326360v1.47","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256043.50901.e3"},{"key":"2025043020264460000_2025.04.27.25326360v1.48","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jalz.2017.01.010","article-title":"How to handle adsorption of cerebrospinal fluid amyloid \u03b2 (1\u201342) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the A\u03b242\/A\u03b240 ratio","volume":"13","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.49","first-page":"179","article-title":"Plasma amyloid \u03b2 42\/40 ratios as biomarkers for amyloid \u03b2 cerebral deposition in cognitively normal individuals. Alzheimer\u2019s & Dementia: Diagnosis","volume":"8","year":"2017","journal-title":"Assessment & Disease Monitoring"},{"key":"2025043020264460000_2025.04.27.25326360v1.50","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Grijalba V , Arbizu J , Romero J , Prieto E , Pesini P , Sarasa L , et al. Plasma A\u03b242\/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross- sectional analysis from the AB255 Study. Alz Res Therapy. 2019;11:96.","DOI":"10.1186\/s13195-019-0549-1"},{"key":"2025043020264460000_2025.04.27.25326360v1.51","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013211"},{"key":"2025043020264460000_2025.04.27.25326360v1.52","first-page":"510","article-title":"Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimer\u2019s & Dementia: Diagnosis","volume":"11","year":"2019","journal-title":"Assessment & Disease Monitoring"},{"key":"2025043020264460000_2025.04.27.25326360v1.53","first-page":"e12405","article-title":"Predicting continuous amyloid PET values with CSF and plasma A\u03b242\/A\u03b240. Alzheimer\u2019s & Dementia: Diagnosis","volume":"15","year":"2023","journal-title":"Assessment & Disease Monitoring"},{"key":"2025043020264460000_2025.04.27.25326360v1.54","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12148-5"},{"key":"2025043020264460000_2025.04.27.25326360v1.55","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes","volume":"78","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025043020264460000_2025.04.27.25326360v1.56","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5847"},{"key":"2025043020264460000_2025.04.27.25326360v1.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15120-3"},{"key":"2025043020264460000_2025.04.27.25326360v1.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2019.04.120"},{"key":"2025043020264460000_2025.04.27.25326360v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4443"},{"key":"2025043020264460000_2025.04.27.25326360v1.60","doi-asserted-by":"crossref","unstructured":"Mattsson-Carlgren N , Andersson E , Janelidze S , Ossenkoppele R , Insel P , Strandberg O , et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Science Advances. 2020;6:eaaz2387.","DOI":"10.1126\/sciadv.aaz2387"},{"key":"2025043020264460000_2025.04.27.25326360v1.61","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.12134"},{"key":"2025043020264460000_2025.04.27.25326360v1.62","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes","volume":"77","year":"2020","journal-title":"JAMA Neurology"},{"key":"2025043020264460000_2025.04.27.25326360v1.63","doi-asserted-by":"crossref","unstructured":"Robbins M , Clayton E , Kaminski Schierle GS . Synaptic tau: A pathological or physiological phenomenon? Acta Neuropathol Commun. 2021;9:149.","DOI":"10.1186\/s40478-021-01246-y"},{"key":"2025043020264460000_2025.04.27.25326360v1.64","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320106"},{"key":"2025043020264460000_2025.04.27.25326360v1.65","doi-asserted-by":"crossref","unstructured":"65. Ingannato A , Bagnoli S , Mazzeo S , Giacomucci G , Bessi V , Ferrari C , et al. Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia. Front Endocrinol [Internet]. 2024 [cited 2024 Sep 23];15. Available from: https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2024.1375302\/full","DOI":"10.3389\/fendo.2024.1375302"},{"key":"2025043020264460000_2025.04.27.25326360v1.66","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial Alzheimer disease","volume":"89","year":"2017","journal-title":"Neurology"},{"key":"2025043020264460000_2025.04.27.25326360v1.67","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac407"},{"key":"2025043020264460000_2025.04.27.25326360v1.68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47286-5"},{"key":"2025043020264460000_2025.04.27.25326360v1.69","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1002\/alz.13156","article-title":"Preanalytical stability of plasma\/serum brain-derived tau","volume":"19","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2025043020264460000_2025.04.27.25326360v1.70","doi-asserted-by":"crossref","unstructured":"Yang Z , Sreenivasan K , Toledano Strom EN , Osse AML , Pasia LG , Cosme CG , et al. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2023;15:190.","DOI":"10.1186\/s13195-023-01340-4"},{"key":"2025043020264460000_2025.04.27.25326360v1.71","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/alz.12787","article-title":"Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance","volume":"19","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.04.27.25326360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:34:46Z","timestamp":1768509286000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.04.27.25326360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":71,"URL":"https:\/\/doi.org\/10.1101\/2025.04.27.25326360","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13195-025-01803-w","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,4,28]]},"subtype":"preprint"}}